Effect of angiotensin AT 2 and muscarinic receptor blockade on osmotically induced vasopressin release

By Hohle S.   Culman J.   Boser M.   Qadri F.   Unger T.  

European Journal of Pharmacology, Vol. 300, Iss. 1, 1996-04 ,pp. : 119-123

Elsevier

Access to resources Recommend Favorite

In vitro pharmacology of an angiotensin AT 1 receptor antagonist with balanced affinity for AT 2 receptors

By Chang R.S.L.   Lotti V.J.   Tsing-Bau C.   O'Malley S.S.   Bendesky R.J.   Kling P.J.   Kivlighn S.D.   Siegl P.K.S.   Ondeyka D.   Greenlee W.J.   Mantlo N.B.  

European Journal of Pharmacology, Vol. 294, Iss. 2, 1995-12 ,pp. : 429-437

Elsevier

Access to resources Recommend Favorite

Valsartan: a novel angiotensin Type 1 receptor antagonist

By Thürmann P.A.  

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 2, 2000-01 ,pp. : 337-350

Informa Healthcare

Access to resources Recommend Favorite

The selective angiotensin AT 1 receptor antagonist LR-B/081 potently inhibits drinking induced by central injection of angiotensin II in rats

By Polidori C.   Ciccocioppo R.   Pompei P.   Cirillo R.   Massi M.  

European Journal of Pharmacology, Vol. 277, Iss. 2, 1995-04 ,pp. : 223-228

Elsevier

Access to resources Recommend Favorite

Lixivaptan: a novel vasopressin receptor antagonist

By Ku Elaine   Nobakht Niloofar   Campese Vito M  

Expert Opinion on Investigational Drugs, Vol. 18, Iss. 5, 2009-05 ,pp. : 657-662

Informa Healthcare

Access to resources Recommend Favorite